NRXP Stock Analysis: NRX Pharmaceuticals | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 165m USD | 12M Return: 23.4% | Charts, Fundamentals & Technical Analysis

Antidepressants, Ketamine Therapies, Bipolar Treatments, CNS Drugs
Total Rating 49
Safety 80
Buy Signal 0.92
Biotechnology
Industry Rotation: +30.9
Market Cap: 165M
Avg Turnover: 3.66M
Risk 3d forecast
Volatility87.9%
VaR 5th Pctl13.7%
VaR vs Median-4.91%
Reward TTM
Sharpe Ratio0.61
Rel. Str. IBD91.4
Rel. Str. Peer Group58
Character TTM
Beta0.775
Beta Downside0.249
Hurst Exponent0.388
Drawdowns 3y
Max DD83.45%
CAGR/Max DD-0.02
CAGR/Mean DD-0.04
EPS (Earnings per Share) EPS (Earnings per Share) of NRXP over the last years for every Quarter: "2021-06": -6.51, "2021-09": -0.4, "2021-12": -0.53, "2022-03": -0.21, "2022-06": -0.11, "2022-09": -0.14, "2022-12": -0.16, "2023-03": -0.16, "2023-06": -0.12, "2023-09": -0.07, "2023-12": -0.5, "2024-03": -0.74, "2024-06": -0.67, "2024-09": -0.15, "2024-12": -0.77, "2025-03": -0.34, "2025-06": -0.98, "2025-09": -0.27, "2025-12": 0.1833, "2026-03": -0.0444,
Last SUE: 0.19
Qual. Beats: 0
Revenue Revenue of NRXP over the last years for every Quarter: 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.008, 2024-03: 0.008, 2024-06: 0, 2024-09: 0, 2024-12: 0.004, 2025-03: 0.004, 2025-06: 0, 2025-09: 0.242, 2025-12: 0.983, 2026-03: 1.068,
Last SUE: -4.00
Qual. Beats: -3

Warnings

Negative Equity With Losses: Insolvent Profile
Strong Share Dilution
Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone

Tailwinds

Rs Leader

Seasonality 8.6 years of data

Jan +0.1% 11
Feb -2.3% 15
Mar +0.1% 2
Apr +4.5% 12
May +6.2% 6
Jun -8.6% 15
Jul -0.9% 9
Aug -1.2% 20
Sep +0.6% 9
Oct +0.6% 20
Nov +0.1% 8
Dec +6.1% 25

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: NRXP NRX Pharmaceuticals

NRX Pharmaceuticals, Inc. (NASDAQ: NRXP) is a U.S.-based, clinical-stage biopharmaceutical company founded in 2015 and headquartered in Wilmington, Delaware. The company focuses on developing therapeutics for central nervous system (CNS) disorders, including suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia, operating through two segments: NRx (drug development) and Dura (interventional psychiatry services). Its pipeline includes NRX-101, a fixed-dose combination of D-cycloserine and lurasidone in Phase 2/3 testing for bipolar depression with suicidal ideation; NRX-100, a preservative-free intravenous ketamine formulation for suicidal depression; and KETAFREE, a generic preservative-free ketamine product.

In addition to its drug development efforts, the company provides precision-based interventional psychiatry services for treatment-resistant depression and PTSD, offering treatments such as transcranial magnetic stimulation (TMS), ketamine infusion therapy, stellate ganglion blocks, Spravato administration, psychotherapy, and medication management. The company holds a development and license agreement with Glytech LLC. As a clinical-stage biotech, NRXP has no commercially approved products and is reliant on capital markets, partnerships, and service revenue to fund its R&D operations; the hybrid drug-development-and-treatment-services model is relatively uncommon among micro-cap CNS-focused biopharmaceutics.

Headlines to Watch Out For
  • NRX-101 Phase 3 data in suicidal bipolar depression due
  • Interventional psychiatry clinic revenue scales on Spravato and TMS demand
  • Cash burn forces dilutive financings to fund NRX-100 NDA filing
Piotroski VR-10 (Strict) 1.0
Net Income: -24.5m TTM > 0 and > 6% of Revenue
FCF/TA: -2.01 > 0.02 and ΔFCF/TA 113.7 > 1.0
NWC/Revenue: -776.9% < 20% (prev -319k%; Δ 318k% < -1%)
CFO/TA -1.25 > 3% & CFO -14.9m > Net Income -24.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 0.29 > 1.5 & < 3
Outstanding Shares: last quarter (32.3m) vs 12m ago 96.99% < -2%
Gross Margin: 77.98% > 18% (prev 25.0%; Δ 52.98% > 0.5%)
Asset Turnover: 23.53% > 50% (prev 0.11%; Δ 23.42% > 0%)
Interest Coverage Ratio: -10.83 > 6 (EBIT TTM -9.79m / Interest Expense TTM 904k)
Altman Z'' -15.00
A: -1.50 (Total Current Assets 7.36m - Total Current Liabilities 25.2m) / Total Assets 11.9m
B: -25.90 (Retained Earnings -308.3m / Total Assets 11.9m)
C: -1.00 (EBIT TTM -9.79m / Avg Total Assets 9.75m)
D: -0.54 (Book Value of Equity -13.8m / Total Liabilities 25.7m)
Altman-Z'' = -101.6 = D
What is the price of NRXP shares?

As of July 08, 2026, the stock is trading at USD 4.16 with a total of 959,976 shares traded. Over the past week, the price has changed by +4.00%, over one month by -3.93%, over three months by +86.55% and over the past year by +23.44%.

Current recommended Stop Loss: 3.70 (which is 11.1% or 1.4 ATR below the current price).

Is NRXP a buy, sell or hold?

NRX Pharmaceuticals has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy NRXP.

  • StrongBuy: 3
  • Buy: 0
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the NRXP price?
Analysts Target Price 42 909.6%
NRX Pharmaceuticals (NRXP) - Fundamental Data Overview as of 03 July 2026
Market Cap USD = 165.2m (165.2m USD * 1.0 USD.USD)
P/E Forward = 34.2466
P/S = 72.0495
P/B = 2.9042
Revenue TTM = 2.29m USD
EBIT TTM = -9.79m USD
EBITDA TTM = -9.48m USD
Long Term Debt = 543k USD (estimated: total debt 934k - short term 391k)
Short Term Debt = 391k USD (from shortTermDebt, last quarter)
Debt = 934k USD (from shortLongTermDebtTotal, last quarter) (leases 934k already included)
Net Debt = -5.78m USD (calculated: Debt 934k - CCE 6.71m)
Enterprise Value = 159.4m USD (165.2m + Debt 934k - CCE 6.71m)
Interest Coverage Ratio = -10.83 (Ebit TTM -9.79m / Interest Expense TTM 904k)
EV/FCF = -6.68x (Enterprise Value 159.4m / FCF TTM -23.9m)
FCF Yield = -14.97% (FCF TTM -23.9m / Enterprise Value 159.4m)
 FCF Margin = -1.04k% (FCF TTM -23.9m / Revenue TTM 2.29m)
 Net Margin = -1.07k% (Net Income TTM -24.5m / Revenue TTM 2.29m)
 Gross Margin = 77.98% ((Revenue TTM 2.29m - Cost of Revenue TTM 505k) / Revenue TTM)
Gross Margin QoQ = 25.47% (prev 48.32%)
Tobins Q-Ratio = 13.39 (Enterprise Value 159.4m / Total Assets 11.9m)
 Interest Expense / Debt = 96.79% (Interest Expense 904k / Debt 934k)
 Taxrate = 21.0% (US federal default 21%)
NOPAT = -7.73m (EBIT -9.79m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.25 (Total Current Assets 7.36m / Total Current Liabilities 29.6m)
 Debt / Equity = -0.07 (negative equity) (Debt 934k / totalStockholderEquity, last quarter -13.8m)
 Debt / EBITDA = 0.61 (negative EBITDA) (Net Debt -5.78m / EBITDA -9.48m)
 Debt / FCF = 0.24 (negative FCF - burning cash) (Net Debt -5.78m / FCF TTM -23.9m)
 Total Stockholder Equity = -22.8m (last 4 quarters mean from totalStockholderEquity)
 RoA = -251.8% (out of range, set to none)
 RoE = 107.7% (negative equity) (Net Income TTM -24.5m / Total Stockholder Equity -22.8m)
 RoCE = 44.01% (negative capital employed) (EBIT -9.79m / Capital Employed (Equity -22.8m + L.T.Debt 543k))
 RoIC = 59.48% (negative operating profit) (NOPAT -7.73m / Invested Capital -13.0m)
 WACC = 8.66% (E(165.2m)/V(166.1m) * Re(8.71%) + (debt cost/tax rate unavailable))
Discount Rate = 8.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 53.94 | Cagr: -34.56%
 [DCF] Fair Price = unknown (Cash Flow -23.9m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.19 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -4.0 | # QB: -3
EPS current Quarter (2026-06-30): EPS=-0.13 | Chg30d=N/A | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.08 | Chg30d=-300.00% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.36 | Chg30d=-376.92% | Revisions=-25% | GrowthEPS=+73.1% | GrowthRev=+732.0%
EPS next Year (2027-12-31): EPS=0.50 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+238.9% | GrowthRev=+1524.9%